Are value-based pricing arrangements more common than we thought?

The answer appears to be ‘yes’ according to a survey by Mahendraratnam et al. (2019). After surveying subject matter experts that were senior representatives from payer organizations and pharmaceutical manufacturers on value-based pricing arrangements (VBA), they found: More than 70% of VBAs implemented between 2014 and 2017 were not publicly disclosed. Furthermore, although consideration of…

ICER and Unsupported Price Increases

The Institute for Clinical and Economic Review (ICER) recently announced that it would annually review treatments with significant price increases to determine if these changes are unsupported by evidence on value. I was recently interviewed by Radar on Specialty Pharmacy to discuss the topic. Jason Shafrin, Ph.D., a senior director of policy and economics at…

Open-Source Decision Model for Value Assessment Rheumatoid Arthritis Treatments

In a recently published paper in PharmacoEconomics, I–along with co-authors Devin Incerti, Jeff Curtis, Darius Lakdawalla, and Jeroen Jansen–describe a recently developed open-source platform for measuring the value of treatments for rheumatoid arthritis. The model itself is here, but and the abstract from Incerti et al. (2019) is below: Objective The nature of model-based cost-effectiveness…

Who uses medical marijuana?

A number of medical studies have touted the benefits of medical marijuana. But who actually uses medical cannibis? Some statistics from Boenhke et al. (2019) provide the answer: While conventional wisdom hold that medical marijuana is frequently used for glaucoma, in practice, this medical marijuana is much more likely to be used to treat other…